AI Article Synopsis
- Epstein-Barr virus (EBV) can lead to B-cell lymphoproliferations in solid organ transplant recipients due to inadequate control of infected B cells.
- Antiviral treatment with foscarnet, a viral-DNA polymerase inhibitor, showed promising results in patients with EBV-associated post-transplant lymphoproliferative disease (PTLD), leading to complete remission in three cases.
- The effectiveness of antiviral treatment was linked to the presence of the lytic phase antigen BZLF1/ZEBRA in PTLD tissue samples, indicating active EBV replication.
Article Abstract
Epstein-Barr virus (EBV)-associated B-cell lymphoproliferations may arise in solid organ transplant recipients. In these patients, an insufficient control of EBV-infected B cells commonly occurs. Antiviral treatment against EBV may represent a causal, relatively low-toxic treatment option. Treatment with foscarnet, an inhibitor of viral-DNA polymerase, in three patients with EBV-associated post-transplant lymphoproliferative disease (PTLD) after heart (n = 2) and heart/kidney transplantation (n = 1), who did not respond to, or were not eligible for reduction of immunosuppression, resulted in complete remission (48+, 27 and 15 months respectively). Response of PTLD to antiviral treatment correlated with the expression of lytic phase antigen BZLF1/ZEBRA protein, an early antigen of lytic EBV-activity, in the biopsied PTLD specimens.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1365-2141.2002.03764.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Plasma anti-CD4 IgG levels are associated with poor immune recovery in people with HIV initiating antiretroviral therapy.
AIDS
February 2025
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY.
A segment of people with HIV on effective antiretroviral therapy (ART) continue to experience poor immune recovery, leaving them at heightened risk of non-AIDS-defining events (NAEs). The production of anti-CD4 IgG autoreactive antibodies is suggested as one contributing mechanism to these complications. Here, we found that plasma anti-CD4 levels do not discriminate immunological responders from nonresponders nor predict the occurrence of NAEs, suggesting it is unlikely a contributing immunopathological factor associated with these complications.
View Article and Find Full Text PDFExamining the risk of delirium in patients hospitalized with COVID-19: Insights from the homeless population.
PLoS One
January 2025
Department of Diagnostic and Health Sciences, College of Health Professions, University of Tennessee Health Science Center, Memphis, TN, United States of America.
For patients hospitalized with COVID-19, delirium is a serious and under-recognized complication, and people experiencing homelessness (PEH) may be at greater risk. This retrospective cohort study compared delirium-associated risk factors and clinical outcomes between PEH and non-PEH. This study used patient records from 154 hospitals discharged from 2020-2021 from the Texas Inpatient Public Use Data file.
View Article and Find Full Text PDFAchieving the state of Georgia 25% HIV incidence reduction target among men who have sex with men in Atlanta through expanded use of multimodal pre-exposure prophylaxis: A mathematical model.
PLoS One
January 2025
Maple Health Group, LLC, New York, United States of America.
The US faces substantial demographic and geographic disparities in both HIV burden and access to pre-exposure prophylaxis (PrEP), an effective strategy to prevent HIV acquisition. Long-acting cabotegravir (CAB) is a novel, injectable PrEP option which demonstrated superior reduction in risk of HIV acquisition compared to daily-oral PrEP in the HPTN083 trial. We modelled the impact of increased PrEP initiations and the introduction of long-acting CAB on HIV incidence among men who have sex with men (MSM) in Atlanta, Georgia, a population with a high burden of HIV.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
National Yang Ming Chiao Tung University, Taipei, NA, Taiwan.
Background: Previous research established a potential relationship between human herpesvirus (HHV) infections and increased risk of dementia. However, whether use of antiherpetic medications may lower dementia risk was not clear. Thus, this systematic review and meta-analysis of cohort studies aimed to investigate the associations between anti-herpetic medications and dementia risk.
View Article and Find Full Text PDFResistance-associated substitutions (RASs) are mutations within the hepatitis C (HCV) genome that may influence the likelihood of achieving a sustained virological response (SVR) with direct acting antiviral (DAA) treatment. Clinicians conduct RAS testing to adapt treatment regimens with the intent of improving the likelihood of cure. The Canadian Network Undertaking against Hepatitis C (CANUHC) prospective cohort consists of chronic HCV patients enrolled between 2015 and 2023 across 17 Canadian sites.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!